The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease

Coffee consumption and all-cause and cause-specific mortality: a meta-analysis by potential modifiers

(2019) Youngyo Kim et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospective, multicenter study

(2019) Mutsumi Iijima et al.   EXPERT OPINION ON PHARMACOTHERAPY

The physiological effects of caffeine on synaptic transmission and plasticity in the mouse hippocampus selectively depend on adenosine A1 and A2A receptors

(2019) João P. Lopes et al.   BIOCHEMICAL PHARMACOLOGY

A new therapeutic strategy with istradefylline for postural deformities in Parkinson’s disease

(2019) Shinsuke Fujioka et al.   Neurologia i Neurochirurgia Polska

The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease

(2018) Keita Matsuura et al.   NEUROSCIENCE LETTERS

Association of coffee consumption and non-motor symptoms in drug-naïve, early-stage Parkinson's disease

(2018) Bang-Hoon Cho et al.   PARKINSONISM & RELATED DISORDERS

Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson’s Disease: A Recent Update and Challenge

(2018) Jiyue Zheng et al.   ACS Chemical Neuroscience

Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?

(2018) Margherita Torti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs

(2018) Delphine Charvin et al.   NATURE REVIEWS DRUG DISCOVERY

Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan

(2018) Makio Takahashi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effect of istradefylline on mood disorders in Parkinson's disease

(2018) Hiroshi Nagayama et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Impact of genetic variations in ADORA2A gene on depression and symptoms: a cross-sectional population-based study

(2018) Sílvia Oliveira et al.   Purinergic Signalling

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

(2017) Fabrizio Stocchi et al.   NEUROLOGY

The effect of istradefylline for Parkinson’s disease: A meta-analysis

(2017) Wataru Sako et al.   Scientific Reports

How does adenosine control neuronal dysfunction and neurodegeneration?

(2016) Rodrigo A. Cunha   JOURNAL OF NEUROCHEMISTRY

The epidemiology of Parkinson's disease: risk factors and prevention

(2016) Alberto Ascherio et al.   LANCET NEUROLOGY

An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models

(2016) Wai Kin D. Ko et al.   NEUROPHARMACOLOGY

A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease

(2015) Tomoyoshi Kondo et al.   CLINICAL NEUROPHARMACOLOGY

Inactivation of adenosine A 2A receptors reverses working memory deficits at early stages of Huntington's disease models

(2015) Wei Li et al.   NEUROBIOLOGY OF DISEASE

Optogenetic Activation of Adenosine A2A Receptor Signaling in the Dorsomedial Striatopallidal Neurons Suppresses Goal-Directed Behavior

(2015) Yan Li et al.   NEUROPSYCHOPHARMACOLOGY

Caffeine acts through neuronal adenosine A2Areceptors to prevent mood and memory dysfunction triggered by chronic stress

(2015) Manuella P. Kaster et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease

(2015) Robert A. Hauser et al.   JAMA Neurology

Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

(2014) Annalisa Pinna   CNS DRUGS

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial

(2014) Robert A Hauser et al.   LANCET NEUROLOGY

Overexpression of Adenosine A2A Receptors in Rats: Effects on Depression, Locomotion, and Anxiety

(2014) Joana E. Coelho et al.   Frontiers in Psychiatry

Caffeine and adenosine A2Areceptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease

(2013) Nélio Gonçalves et al.   ANNALS OF NEUROLOGY

Regulation of Fear Responses by Striatal and Extrastriatal Adenosine A2A Receptors in Forebrain

(2013) Catherine J. Wei et al.   BIOLOGICAL PSYCHIATRY

Istradefylline: First Global Approval

(2013) Rosselle Dungo et al.   DRUGS

Adenosine A2A Receptor Deficiency Alleviates Blast-Induced Cognitive Dysfunction

(2013) Ya-Lei Ning et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

(2013) Stewart A. Factor et al.   MOVEMENT DISORDERS

Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

(2013) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Adenosine receptors as drug targets — what are the challenges?

(2013) Jiang-Fan Chen et al.   NATURE REVIEWS DRUG DISCOVERY

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects

(2012) D. L. Cutler et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

“No Thanks, Coffee Keeps Me Awake”: Individual Caffeine Sensitivity Depends on ADORA2A Genotype

(2012) Hans-Peter Landolt   SLEEP

Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease

(2011) R. A. Popat et al.   EUROPEAN JOURNAL OF NEUROLOGY

Preclinical jockeying on the translational track of adenosine A2A receptors

(2011) Melita T. Barkhoudarian et al.   EXPERIMENTAL NEUROLOGY

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM

(2011) N Amin et al.   MOLECULAR PSYCHIATRY

Genome-Wide Gene-Environment Study Identifies Glutamate Receptor Gene GRIN2A as a Parkinson's Disease Modifier Gene via Interaction with Coffee

(2011) Taye H. Hamza et al.   PLoS Genetics

Recent developments in adenosine receptor ligands and their potential as novel drugs

(2010) Christa E. Müller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease

(2010) Danqing Xiao et al.   BRAIN RESEARCH

An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

(2010) David J. Brooks et al.   CLINICAL NEUROPHARMACOLOGY

Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: Rationale and design of a prospective, randomized, multicenter study

(2010) Furqan H. Tejani et al.   JOURNAL OF NUCLEAR CARDIOLOGY

Adenosine A2A receptor gene: Evidence for association of risk variants with panic disorder and anxious personality

(2010) Christa Hohoff et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Genetics of caffeine consumption and responses to caffeine

(2010) Amy Yang et al.   PSYCHOPHARMACOLOGY

Recent Caffeine Ingestion Reduces Adenosine Efficacy in the Treatment of Paroxysmal Supraventricular Tachycardia

(2009) Miguel S. Cabalag et al.   ACADEMIC EMERGENCY MEDICINE

Preferential enhancement of working memory in mice lacking adenosine A2A receptors

(2009) Sai-jun Zhou et al.   BRAIN RESEARCH

Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition

(2009) Hai-Ying Shen et al.   Current Neuropharmacology

Adenosine A2A Receptor Blockade Prevents Synaptotoxicity and Memory Dysfunction Caused by  -Amyloid Peptides via p38 Mitogen-Activated Protein Kinase Pathway

(2009) P. M. Canas et al.   JOURNAL OF NEUROSCIENCE

Adenosine, adenosine A2A antagonists, and Parkinson's disease

(2009) P. Jenner et al.   PARKINSONISM & RELATED DISORDERS

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders

(2008) Rodrigo Cunha et al.   CURRENT PHARMACEUTICAL DESIGN

Genetic inactivation of adenosine A2A receptors attenuates acute traumatic brain injury in the mouse cortical impact model

(2008) Wei Li et al.   EXPERIMENTAL NEUROLOGY

Nucleus Accumbens Adenosine A2A Receptors Regulate Exertion of Effort by Acting on the Ventral Striatopallidal Pathway

(2008) S. Mingote et al.   JOURNAL OF NEUROSCIENCE

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity

(2008) Marc Flajolet et al.   NATURE NEUROSCIENCE

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk

(2007) Karen M. Powers et al.   MOVEMENT DISORDERS